Hiroko Bando

University of Tsukuba, Tsukuba, Ibaraki, Japan

Are you Hiroko Bando?

Claim your profile

Publications (64)188.43 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary breast and ovarian cancer syndrome (HBOC) is a significant type of familial ovarian cancer. A survey of gynecologic oncologists was conducted in order to characterize the state of care and awareness of information provision for HBOC in Japan and to identify information necessary to enhance HBOC care. All gynecologic oncologists certified by the Japan Society of Gynecologic Oncology (JSGO) as specialists in the treatment of ovarian cancer were included. They were sent a 44-question questionnaire dealing with the background of the respondent, the facilities at the respondent's medical institution, how the family history interview is conducted, awareness of and practice behavior toward HBOC, performance of genetic testing, and performance of risk-reducing salpingo-oophorectomy (RRSO). The response rate was 50.1 %. About 60 % of respondents stated that "I administer care with HBOC in mind" and "I want to be involved in the care of HBOC." However, only 2 in 3 doctors was able to explain HBOC to patients, fewer than 1 in 5 doctors was able to give counseling to patients, 1 in 10 doctors provided printed information to patients suspected of having a hereditary cancer, and 1 in 7 doctors recommended that patients suspected of having a hereditary cancer visit the department of genetics. The provision of information to patients, recommending that patients visit the department of genetics, and the performance of genetic testing were dependent on whether a department of genetics was present in the respondent's institution. The survey also found that RRSO is not widely performed in Japan.
    Familial Cancer 05/2014; · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to reveal the background to the image variations in strain elastography (strain imaging [SI]) depending on the manner of manipulation (compression magnitude) during elasticity image (EI) acquisition. Thirty patients with 33 breast lesions who had undergone surgery followed by SI assessment in vivo were analyzed. An analytical approach to tissue elasticity based on the stress-elastic modulus (Young's modulus) relationship was adopted. Young's moduli were directly measured ex vivo in surgical specimens ranging from 2.60 kPa (fat) to 16.08 kPa (invasive carcinoma) under the weak-stress condition (<0.2-0.4 kPa, which corresponds to the appropriate "light touch" technique in SI investigation. The contrast (ratio) of lesion to fat in elasticity ex vivo gradually decreased as the stress applied increased (around 1.0 kPa) on the background of significant non-linearity of the breast tissue. Our results indicate that the differences in non-linearity in elasticity between the different tissues within the breast under minimal stress conditions are closely related to the variation in EI quality. The significance of the "pre-load compression" concept in tissue elasticity evaluation is recognized. Non-linearity of elasticity is an essential attribute of living subjects and could provide useful information having a considerable impact on clinical diagnosis in quantitative ultrasound elastography.
    Ultrasound in medicine & biology 05/2014; · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment-related infertility is one of the important quality-of-life issues in young breast cancer (YBC) patients. Although existing guidelines recommend supporting fertility preservation (FP) of YBC, the perceptions of reproductive specialists (RS) has not been evaluated. We investigated the perceptions and needs of RS with regard to FP of YBC patients. A cross-sectional survey was sent to 423 certified RS registered to the Japan Society for Reproductive Medicine to self-evaluate their perceptions and needs regarding FP in YBC patients. Two hundred RS (47 %) responded to the survey. 99 % responded that RS should be engaged in FP of YBC patients. 88 % responded that they would like to treat YBC patients, while 46 % responded that cancer treatment is more important than childbirth, even when the patient is recurrence-free 5 years after primary treatment. Respondents affiliated to private clinics were more likely to accept both fertilized and unfertilized egg preservation than those affiliated with academic or general hospitals. 70 % responded that they were anxious about treating breast cancer patients: concerns regarding a greater or unknown risk of recurrence (66 %), insufficient knowledge about breast cancer (47 %), and lack of a patient's spouse/partner (24 %) were identified as major barriers in supporting FP for YBC patients. RS recognize the need for FP in YBC patients and are willing to participate in their care. Affiliation of RS was related to a positive attitude to egg preservation. Various concerns regarding FP among RS indicate the need for evidence that supports the safety of FP, inter-disciplinary communication, and practice guidelines.
    International Journal of Clinical Oncology 02/2014; · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This randomized, multicenter study compared the efficacy of docetaxel with or without capecitabine following fluorouracil/epirubicin/cyclophosphamide (FEC) therapy in operable breast cancer and investigated the role of Ki67 as a predictive biomarker. Patients were randomized to 4 cycles of docetaxel/capecitabine (docetaxel: 75 mg/m(2) on day 1; capecitabine: 1,650 mg/m(2) on days 1-14 every 3 weeks) or docetaxel alone (75 mg/m(2) on day 1 every 3 weeks) after completion of 4 cycles of FEC (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 every 3 weeks). The primary endpoint was the pathological complete response (pCR) rate. Predictive factor analysis was conducted using clinicopathological markers, including hormone receptors and Ki67 labeling index (Ki67LI). A total of 477 patients were randomized; the overall response in the docetaxel/capecitabine and docetaxel groups was 88.3 and 87.4 %, respectively. There were no significant differences in the pCR rate (docetaxel/capecitabine: 23 %; docetaxel: 24 %; p = 0.748), disease-free survival, or overall survival. However, patients with mid-range Ki67LI (10-20 %) showed a trend towards improved pCR rate with docetaxel/capecitabine compared to docetaxel alone. Furthermore, multivariate logistic regression analysis showed pre-treatment Ki67LI (odds ratio 1.031; 95 % CI 1.014-1.048; p = 0.0004) to be a significant predictor of pCR in this neoadjuvant treatment setting. Docetaxel/capecitabine (after 4 cycles of FEC) did not generate significant improvement in pCR compared to docetaxel alone. However, exploratory analyses suggested that assessment of pre-treatment Ki67LI may be a useful tool in the identification of responders to preoperative docetaxel/capecitabine in early-stage breast cancer.
    Breast Cancer Research and Treatment 10/2013; · 4.47 Impact Factor
  • Hiroko Bando
    [Show abstract] [Hide abstract]
    ABSTRACT: About 5-10 % of breast cancer cases are considered to be hereditary, and germ line mutations in the BRCA1 and BRCA2 genes have been proven to contribute to the development of hereditary breast and/or ovarian cancer syndrome (HBOC). Breast cancer diagnosed at a young age is an indication of a higher likelihood of HBOC. Risk assessment, genetic counseling, and BRCA1/BRCA2 mutation testing, especially for younger women with breast cancer, have started to be an integral element of practice due to advances in gene sequencing technologies and accumulating evidence for the clinical implications of BRCA mutation status for not only early breast cancer management, but also for the patient's own and their family's next cancer risk, and proactive steps toward a risk-reducing approach. As yet, the cancer genetic service system is immature in Japan. There are several problems to be solved to improve cancer genetic services in clinical practice for breast cancer.
    Breast Cancer 06/2013; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nomogram, a standard technique that utilizes multiple characteristics to predict efficacy of treatment and likelihood of a specific status of an individual patient, has been used for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. The aim of this study was to develop a novel computational technique to predict the pathological complete response (pCR) to NAC in primary breast cancer patients. A mathematical model using alternating decision trees, an epigone of decision tree, was developed using 28 clinicopathological variables that were retrospectively collected from patients treated with NAC (n = 150), and validated using an independent dataset from a randomized controlled trial (n = 173). The model selected 15 variables to predict the pCR with yielding area under the receiver operating characteristics curve (AUC) values of 0.766 [95 % confidence interval (CI)], 0.671-0.861, P value < 0.0001) in cross-validation using training dataset and 0.787 (95 % CI 0.716-0.858, P value < 0.0001) in the validation dataset. Among three subtypes of breast cancer, the luminal subgroup showed the best discrimination (AUC = 0.779, 95 % CI 0.641-0.917, P value = 0.0059). The developed model (AUC = 0.805, 95 % CI 0.716-0.894, P value < 0.0001) outperformed multivariate logistic regression (AUC = 0.754, 95 % CI 0.651-0.858, P value = 0.00019) of validation datasets without missing values (n = 127). Several analyses, e.g. bootstrap analysis, revealed that the developed model was insensitive to missing values and also tolerant to distribution bias among the datasets. Our model based on clinicopathological variables showed high predictive ability for pCR. This model might improve the prediction of the response to NAC in primary breast cancer patients.
    Breast Cancer Research and Treatment 06/2012; 134(2):661-70. · 4.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cystoid macular edema (CME) is a rare complication of taxane-based chemotherapy. We encountered a patient who developed CME during treatment with nab-paclitaxel for metastatic breast cancer. Early detection of this disease enables continuation of appropriate treatment without reducing the quality of life for patients with end-stage disease. Physicians should be aware of this potential adverse effect, and should make changes to the treatment of patients as soon as possible.
    Breast Cancer 05/2012; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-Hodgkin lymphoma (NHL) of the breast is a rare disease. Herein, we report a rare case of secondary involvement of the breast by NHL in a male patient and the ultrasound imaging findings. A 70-year-old man noticed an induration of the subareolar region of the right breast. He had been diagnosed as having mantle cell lymphoma 5 years before and treated with several series of chemoradiotherapy. On supine examination, palpation revealed bilateral breast enlargement, but detection of a lump was difficult. Ultrasonography showed a hypoechoic non-mass image-forming lesion in the subareolar region of the right breast. The final pathological diagnosis was recurrence of mantle cell lymphoma in the right breast. The diagnosis of malignant lymphoma of the breast by imaging modalities is difficult because there are no specific features. Breast lymphoma should be included with gynecomastia and breast cancer in the differential diagnosis of male patients with breast enlargement.
    Breast Cancer 03/2012; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Fertility is one of the key aspects of quality of life for breast cancer patients of childbearing age. The objective of this study was to describe fertility-related practice for young breast cancer patients in Japan and to identify healthcare provider factors that contribute to physicians' behavior towards fertility preservation. METHODS: A cross-sectional survey was developed in order for Japanese breast cancer specialists (n = 843) to self-evaluate their knowledge, attitude, and behavior regarding fertility preservation. Survey items included questions regarding knowledge of and attitude toward fertility issues in cancer patients, fertility-related practice, potential barriers for the discussion of fertility with patients, and responding physicians' socio-demographic background. RESULTS: Four hundred and thirty-four (52%) breast oncologists responded to the survey. Female and younger oncologists (age less than 50 years) had significantly higher probability of referring patients to reproductive specialists. Physicians who had better knowledge score and positive attitudes toward fertility preservation were more likely to discuss potential fertility issues with cancer patients. This was significantly associated with consultation and referral to reproduction specialists when encountering fertility issues with cancer patients. Risk of recurrence, lack of collaborating reproductive specialists, and time constraints in the clinic were identified as major barriers to discussion of fertility preservation with breast cancer patients. CONCLUSION: Female and younger physicians as well as physicians working in a multidisciplinary environment had positive attitudes and behavior towards fertility preservation in breast cancer patients. The development of comprehensive and interdisciplinary programs for healthcare providers is necessary to meet the expectations and fertility needs of breast cancer patients.
    Breast Cancer 01/2012; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This trial is conducted to investigate the benefit of trastuzumab monotherapy compared with a combination therapy of trastuzumab and chemotherapy in women over 70 years with human epidermal growth factor receptor type-2-positive primary breast cancer. Inclusion criteria are the following: histologically diagnosed as invasive breast cancer and received curative operation for primary breast cancer; Stage I, IIA, IIB or IIIA/M0; and baseline left ventricular ejection fraction is ≥55%. Patients are randomized to receive either trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy selected from regimens specified on the protocol or trastuzumab monotherapy. The primary endpoint is disease-free survival. Secondary endpoints are overall survival, relapse-free survival, safety, health-related quality of life, comprehensive geriatric assessment and cost effectiveness. Patients recruitment has been commenced in October 2009. Enrollment of 300 patients is planned during the 4-year recruitment period. We hereby report the study concept.
    Japanese Journal of Clinical Oncology 02/2011; 41(5):709-12. · 1.90 Impact Factor
  • Breast. 01/2011; 20.
  • Ultrasound in Medicine and Biology - ULTRASOUND MED BIOL. 01/2011; 37(8).
  • [Show abstract] [Hide abstract]
    ABSTRACT: EPIDEMIOLOGY OF BREAST CANCER: The incidence and mortality of breast cancer are lower in Asia than in the West, particularly in post-menopausal women, but they are increasing. The age patterns of the incidence of breast cancer in Asia differ from in the West: in most Asian countries the peak incidence of breast cancer is at about age 45-50, whereas in western countries the incidence continues to increase even at older ages. Mortality is decreasing in western countries, whereas it is still increasing in Asian nations. There are many epidemiological factors involved in breast cancer, and important known risk factors include diet, obesity and diabetes. Asian studies found that high intake of isoflavones reduced the risk of breast cancer. PATHOLOGY OF BREAST CANCER: With regard to the pathology of breast cancer, for the molecular subtype, luminal A and luminal B are being used, while HER2 expression and rapid proliferation are also employed. Study results showed a somewhat higher prevalence of luminal A in Japanese compared with Americans. Ductal carcinoma in situ breast cancer is less frequent in Asian breast cancer patients than in Americans. The Working Group resolved to establish an international committee for pathological assessment of breast cancer in Asia. TREATMENT OF BREAST CANCER: Pharmacokinetics-pharmacodynamics studies are needed between ethnic backgrounds, investigating aromatase inhibitors and tamoxifen (endoxifen), as well as the effects of demographic factors such as diet, medical care, body mass index, etc. Correlations between adverse events and the clinical outcome also need to be studied.
    Japanese Journal of Clinical Oncology 09/2010; 40 Suppl 1:i13-18. · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An attempt at refraction-based 2D, 2.5D and 3D X-ray imaging of articular cartilage and breast carcinoma is reported. We are developing very high contrast X-ray 2D imaging with XDFI (X-ray dark-field imaging), X-ray CT whose data are acquired by DEI (diffraction-enhanced imaging) and tomosynthesis due to refraction contrast. 2D and 2.5D images were taken with nuclear plates or with X-ray films. Microcalcification of breast cancer and articular cartilage are clearly visible. 3D data were taken with an X-ray sensitive CCD camera. The 3D image was successfully reconstructed by the use of an algorithm newly made by our group. This shows a distinctive internal structure of a ductus lactiferi (milk duct) that contains inner wall, intraductal carcinoma and multifocal calcification in the necrotic core of the continuous DCIS (ductal carcinoma in situ). Furthermore consideration of clinical applications of these contrasts made us to try tomosynthesis. This attempt was satisfactory from the view point of articular cartilage image quality and the skin radiation dose.
    European journal of radiology 08/2008; 68(3 Suppl):S32-6. · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the development of the CellSearch System, it has become possible to measure circulating tumor cell (CTC) levels with high reproducibility, and the CTC test is currently being used clinically for patients with metastatic breast cancer in the United States. It is imperative that the clinical significance of the CTC test also be examined in Japan. Using the CellSearch System, CTC levels were evaluated in 57 healthy individuals and patients with benign breast disease; 30 patients with primary breast cancer (stages 1-3); and 38 patients with metastatic breast cancer. First, the relationship between CTC levels and the presence of metastasis was examined using a cutoff score of 2 CTCs per 7.5 ml whole blood. Then, the patients with metastatic breast cancer were divided into two groups, using a cutoff score of 5 CTCs per 7.5 ml blood, and progression-free survival (PFS) and overall survival (OS) were compared in the two groups. When the clinical cutoff score was set at 2 CTCs per 7.5 ml blood, 0% of the healthy individuals and patients with benign breast disease (0/57), 3.3% of the patients with primary breast cancer (1/30), and 50% of the patients with metastatic breast cancer (19/38) were identified as as having 2 CTCs per 7.5 ml blood. Additionally, with a cutoff score of 5 CTCs, 11 patients were reported to have 5 or more CTCs and both PFS (P = 0.0036) and OS (P = 0.04) were worse for this patient population than for the population with fewer than 5 CTCs. As concluded in a similar clinical trial in the United States, for patients with breast cancer, measuring CTC levels can be both an accurate indicator of metastases and an important measure of patient prognosis.
    International Journal of Clinical Oncology 07/2008; 13(3):252-6. · 1.73 Impact Factor
  • Ejc Supplements - EJC SUPPL. 01/2008; 6(7):132-132.
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE In 2003, we completed the development of elastography which allows diagnosis by physicians even which little experience in ultrasound, and this technique has been commercialized and marketed since 2004. The performance of diagnosis with elastography is superior or equivalent to the conventional “B-mode diagnosis + color Doppler” modality, with high reliability. It has the additional advantage of being simple and convenient. However one of the issues was the lack of the objectivity in diagnosis based on strain imaging. In the next step we developed a new quantitative method: Fat-Lesion Ratio (FLR) which provides greater objectivity in assessing elastography (strain image). METHOD AND MATERIALS FLR is defined as the ratio value obtained by dividing the mean strain at fat by the mean strain at hypo-echoic lesion. The strain for subcutaneous fat was determined from a circle bounded by the skin and mammary glands, and the strain for the lesion was determined from a circle bounded by the inner margin of the hypo-echoic area. Subjects were 408 cases with hypo-echoic lesions not over 2cm in diameter who have been examined elastography from January 25 2005. Among these subjects were 135 cases of breast cancer (mean age 54.6 ± 11.1, lesion diameter 12.1 ± 4.4 mm) and 271 cases of benign disease (mean age 45.9 ± 10.6, lesion diameter 9.6 ± 4.1). RESULTS The mean value for FLR in breast cancer (14.8) was considerably higher than the mean value for FLR in benign disease (4.47). Using a cut-off point of 4.8, we obtained sensitivity of 76.6%, specificity of 76.8%, and accuracy of 76.7%. Area under the ROC curve was high (0.818), while those of B-mode are 85.9%, 84.1% and 84.7% respectively. Although the accuracy of FLR is lower than that of B-mode, it is significant that FLR alone provided highly reliable diagnostic accuracy. CONCLUSION It is concluded that FLR showed sufficient clinical performance with high diagnostic objectivity not depended on the experience of examiners. CLINICAL RELEVANCE/APPLICATION Just with a short training for FLR method, non-specialized examiners can acquire the equivalent degree of competence for diagnosis as specialists in ultrasonic diagnosis for breast cancer.
    Radiological Society of North America 2007 Scientific Assembly and Annual Meeting; 11/2007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thyroid stimulating hormone (TSH) is known to increase intracytoplasmic cyclic adenosine monophosphate (cAMP) and to regulate the growth of normal follicular cells. The aim of this study was to explore the role of the cAMP-mediated signaling pathway stimulated by TSH as a cell growth modulator in human thyroid cancer cells. One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP. Forskolin suppressed thyroid cancer cell proliferations, especially in K1 cells, in a dose-dependent manner and induced growth arrest at the G0/G1 phase of the cell cycle. We also examined the expression of mitogen activated protein kinase (MAPK) after the forskolin treatment. Forskolin reduced the activation of growth factor induced MAPK activity. In conclusion, we demonstrated that forskolin was involved in G1 arrest and MAPK activation in K1 thyroid cancer cells. Our study suggests that the TSH signal mediated by cAMP acts as a negative regulator in thyroid cancer cells, unlike that in normal follicular cells.
    Oncology Reports 09/2007; 18(2):441-5. · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined the expression of sVEGFR1 in colorectal cancer tissue and corresponding normal colorectal mucosa to assess the clinical significance of sVEGFR1 in colorectal cancer. We also assessed the relationship between sVEGFR1 levels and various clinicopathologic factors and prognoses. sVEGFR1 and VEGF levels were measured in fresh-frozen tumor extracts from 84 primary colorectal cancer tissues and 27 corresponding normal mucosa using ELISA. Mean of sVEGFR1 levels were 3.17 ng/mg protein. sVEGFR1 levels increased significantly in cancer tissue compared with normal mucosa. Although VEGF levels increased in cancer tissues, the ratio of sVEGFR1/VEGF in cancer tissue was significantly lower than that in normal tissue. No significant correlation between sVEGFR1 or VEGF levels and any clinicopathologic parameter was found. Overexpression of sVEGFR1 was significantly associated with a favorable prognosis. Based on sVEGFR1 levels in colorectal cancer without distant metastases, patients with higher sVEGFR1 levels (>=1.5 ng/mg protein) demonstrated significant longer recurrence-free survival than patients with lower sVEGFR1 levels (<1.5 ng/mg protein) (P = 0.0017). Multivariate analysis showed that the sVEGFR1 levels in cancer tissue were an independent prognostic indicator of disease progression. sVEGFR1 expression was significantly elevated in colorectal cancer tissue compared with normal mucosa and the intratumoral balance between sVEGFR1 and VEGF was significantly different between tumor tissue and normal controls. Furthermore, sVEGFR1 levels showed a significant prognostic value. Further studies concerning the biologic and therapeutic significance of sVEGFR1 in colorectal cancer are warranted.
    Cancer Science 03/2007; 98(3):405-10. · 3.48 Impact Factor
  • Hiroko Bando
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer development requires neovascularization. The level of angiogenic activity in breast cancer has been shown to be a determinant of disease progression and survival. Vascular endothelial growth factor (VEGF) is a one of the most essential pro-angiogenic growth factors expressed by most cancer-cell types and certain tumor stromal cells. Blocking the action of VEGF appears to be a promising anti-angiogenic approach to treat multiple types of solid tumors including breast cancer, and clinical trials using agents which target VEGF were launched beginning in the late 1990s. The effort reached fruition in 2005 with the first report of a large, prospective randomized trial of anti-VEGF therapy in patients with metastatic breast cancer (MBC), which demonstrated the benefit of adding the monoclonal antibody bevacizumab to the chemotherapeutic agent paclitaxel. The success of this trial provided proof of principle that inhibition of angiogenesis has the potential to enhance the effectiveness of treatment of this disease. Adjuvant therapy trials are in development with bevacizumab and numerous other anti-VEGF agents are now being tested in patients with breast cancer in various settings. Nevertheless, since bevacizumab monotherapy has minimal activity, a question for future therapeutic development of these agents in breast cancer relates to the interaction between anti-angiogenic strategies and cytotoxic therapies. Further research is still needed for complete understanding of the exact role of VEGF and angiogenesis in health and disease, to take best advantage and avoid the adverse effects of anti-angiogenic therapy.
    Breast Cancer 02/2007; 14(2):163-73. · 1.33 Impact Factor

Publication Stats

1k Citations
188.43 Total Impact Points

Institutions

  • 2008–2014
    • University of Tsukuba
      • Department of Breast-Thyroid-Endocrine Surgery
      Tsukuba, Ibaraki, Japan
  • 2013
    • National Hospital Organization Kyushu Cancer Center
      Hukuoka, Fukuoka, Japan
  • 2010–2012
    • Kyoto University
      • Department of Breast Surgery
      Kyoto, Kyoto-fu, Japan
  • 2001–2007
    • Tokyo Metropolitan Komagome Hospital
      Edo, Tōkyō, Japan
  • 2003–2005
    • Tokyo Metropolitan Cancer and Infectious Diseases Center
      • Department of Surgery
      Edo, Tōkyō, Japan
    • Kokura Memorial Hospital
      Kitakyūshū, Fukuoka, Japan
    • Showa University
      • Department of Surgery
      Shinagawa, Tōkyō, Japan